B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin
- Dimitrios Daoussis†1Email author,
- Athanassios C Tsamandas†2,
- Stamatis-Nick C Liossis†1,
- Ioannis Antonopoulos1,
- Elli Karatza2,
- Georgios Yiannopoulos1 and
- Andrew P Andonopoulos1
© Daoussis et al.; licensee BioMed Central Ltd. 2012
Received: 23 November 2010
Accepted: 14 June 2012
Published: 14 June 2012
Recently, several studies assessing the clinical efficacy of rituximab (RTX) in systemic sclerosis (SSc) have reported encouraging results. We aimed at exploring whether RTX exerts its beneficial effects on fibrosis through attenuation of platelet-derived growth factor receptor (PDGFR) pathway activation.
We immunohistochemically assessed skin biopsies obtained from eight patients with SSc prior to and 6 months following RTX treatment, three control SSc patients (at the same time points) and three healthy subjects. We assessed the expression of platelet-derived growth factor, PDGFR and phosphorylated (activated) PDGFR.
We found a strong correlation of PDGFRα and PDGFRβ expression on spindle-like cells and collagen deposition in SSc biopsies (r = 0.97 and r = 0.96 for PDGFRα and PDGFRβ, respectively; P < 0.0001 for both), indicating a strong link between PDGFR expression and fibrosis. Expression of PDGFRα and PDGFRβ in the papillary dermis significantly decreased following RTX administration (mean ± standard error of the mean at baseline vs. 6 months, respectively: PDGFRα, 42.05 ± 5.03 vs. 26.85 ± 3.00, P = 0.004; and PDGFRβ, 37.14 ± 4.94 vs. 24.01 ± 3.27, P = 0.012). Similarly, expression of phosphorylated PDGFRα and PDGFRβ in the papillary dermis significantly decreased following RTX administration (P = 0.006 and P = 0.013 for phospho-PDGFRα and phospho-PDGFRβ, respectively). No changes in platelet-derived growth factor tissue expression or serum levels were found following RTX treatment.
RTX may favorably affect skin fibrosis through attenuation of PDGFR expression and activation, a finding that supports a disease-modifying role of RTX in SSc. Large-scale, multicenter studies are needed to further explore the efficacy of RTX in SSc.
Systemic sclerosis (SSc) represents one of the most challenging and difficult to treat diseases for rheumatologists. During recent years there has been significant progress towards a better understanding of the complex pathogenesis of the disease; however, this progress has not been translated into novel therapies. Treatment options for patients with SSc are so far limited, while no therapy has definitely shown disease-modifying properties. During the last few years, four studies - including one from our research group - have assessed the potential clinical efficacy of rituximab (RTX) in patients with SSc and have reported encouraging results [1–4]. The rationale for the use of RTX in SSc is based on strong experimental data suggesting a key role for B cells in regulating the fibrotic process [5–9]. Patients treated with RTX showed either an improvement of skin fibrosis or lung function or remained clinically stable; it should be noted, however, that stabilization alone should be considered a positive outcome in this devastating disease where patients tend to gradually worsen over time. In three of those studies where skin biopsies were performed, a significant histologic improvement in terms of reduction of collagen deposition and myofibroblast score was reported [1, 3, 4], suggesting a potential disease-modifying role of RTX in skin fibrosis.
RTX is a monoclonal antibody that targets and depletes B cells but it is not known how this drug may mediate its beneficial effect on fibrosis. Platelet-derived growth factor (PDGF) is a pivotal mediator of fibrosis; it has stimulatory effects on scleroderma fibroblasts by enhancing their proliferation and increasing collagen production . PDGF signals through two structurally similar tyrosine kinase receptors, platelet-derived growth factor receptor (PDGFR)α and PDGFRβ. PDGF leads to homodimerization or heterodimerization of these receptors and to phosphorylation of specific tyrosine residues. In animal models, enhancement of PDGF signaling leads to fibrosis [11, 12]. Moreover agonistic autoantibodies against PDGFR have been found in patients with SSc; these stimulatory autoantibodies have been suggested to participate in disease pathogenesis .
Based on these data, we aimed to explore whether RTX exerts its beneficial effects on fibrosis through attenuation of PDFGR pathway activation. We therefore immunohistochemically assessed the expression of PDGF, PDGFR and phospho-PDGFR, which represents the phosphorylated and therefore active form of the receptor. We report herein imunohistochemical evidence that RTX treatment associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin, indicating that RTX may favorably affect fibrosis through modulation of PDGFR expression/activation.
Materials and methods
Eight patients with diffuse SSc fulfilling the preliminary American College of Rheumatology criteria for the classification of the disease  were enrolled. Demographic and clinical characteristics of these patients have been previously reported [1, 15]. A local ethics committee approved the study protocol (which fulfilled the Declaration of Helsinki requirements) and written informed consent was obtained from all participating individuals.
Patients were subjected to skin biopsies (a 5 mm punch biopsy) prior to and 6 months following RTX administration (consisting of four pulses of RTX (375 mg/m2) weekly). Biopsies were taken from lesional skin in the forearm; the second biopsy was taken from lesional skin adjacent to (always < 2 cm) the site of the baseline biopsy. Skin biopsies were also performed in the same way and at the same time points in three SSc patients who did not receive RTX therapy (two patients treated with cyclophosphamide and one receiving no treatment). Skin biopsies from three healthy subjects were used as controls. All skin biopsies were fixed in 10% neutral buffered formalin and embedded in paraffin.
Collagen deposition was assessed and quantified using computerized image analysis as previously described . Myofibroblasts (alpha smooth muscle actin-positive cells) were detected by a standard streptavidin-biotin peroxidase method using an anti-alpha smooth muscle actin antibody (Novocastra, Newcastle, UK). For the detection of PDGF-AA, PDGF-BB, PDGFRα, PDGFRβ, phospho-PDGFRα and phospho-PDGFRβ we employed a standard streptavidin-biotin peroxidase method (DAKO Cytomation Envision™ Peroxidase DAB;DAKO, Glostrup, Denmark), using the following antibodies: anti-PDGF-AA (Millipore, Billerica, Massachusetts, USA), anti-PDGF-BB (Acris, Herford, Germany), anti-PDGFRα and anti-PDGFRβ (both from Santa-Cruz Biotechnology, Santa-Cruz, California, USA), anti-phospho-PDFRα (phosphoY754; Abcam, Cambridge, UK), and anti-phospho-PDFRβ (phospho Y579; Abcam). The same staining procedure was performed on paraffin sections from human hepatocellular carcinoma, which served as a positive control for PDGFR and phospho-PDGFR staining.
PDGFR and phospho-PDFR were mainly expressed in spindle-like cells resembling fibroblasts, so we employed a high-precision image analysis system (Image-Pro Plus software program; Media Cybernetics, Silver Spring, MD, USA) to quantify the intensity of immunohistochemical staining in these cells, as previously described [16–18]. We used a color camera (KY-F55MD; Olympus, Tokyo, Japan) mounted on an Olympus BX 41F microscope. Each time, before measurements of the images were taken, we standardized the contrast and brightness and calibrated the measurement system with appropriate slides. The latter included the slides that we used as positive controls in the immunohistochemical stains, as were described above. We excluded the edges of the sections from the evaluation.
For quantitation of immunostaining intensities, we measured the inverse mean density based on the RGB color parameter. The circle profile tool of the Image-Pro Plus program was used for measurements of immunostaining of PDGFR and phospho-PDGFR in spindle-like cells. According to previous reports [16, 17], in each case 20 randomly selected color video images of 512 × 512 pixels with a resolution of 0.4348 μm were performed. Measurements were made on a total of 100 cells per specimen (5 cells/image ×20). Measurements were carried out separately for spindle-like cells in the upper and lower dermis. For each set of measurements, a curve was made according to immunostaining intensity. The units arbitrarily ranged from 0 (intensity absent) to 230 (top intensity). In all immunohistochemical procedures, for negative-control purposes, the same techniques were used on tissue sections in which 1% BSA in PBS substituted the primary antibody in each case. All biopsies were evaluated simultaneously in a blinded (to treatment and date) fashion. Serum levels of PDGF-AA and PDGF-BB were measured by employing ELISA methodology using commercially available kits (both from R&D Systems, Minneapolis, MN, USA).
Statistical analysis was performed using the GraphPad Prism software version 5 (GraphPad Software, La Jolla, CA, USA). Pearson correlation and a paired t test were used as indicated.
Clinical and histological outcomes following RTX treatment have been reported previously [1, 15]. Briefly, we found a significant improvement of skin thickening, as clinically assessed, which coincided with histologic improvement (reduction of collagen deposition and myofibroblast score) in six out of eight patients. Histologic improvement was associated with depletion of skin-infiltrating B cells.
PDGFR expression on spindle-like cells in scleroderma skin is strongly associated with collagen deposition and attenuates following rituximab administration
We first studied, by immunohistochemistry, the expression of PDGFRα and PDGFRβ in scleroderma versus normal skin. Expression of PDGFRα and PDGFRβ could not be detected in spindle-like cells in the dermis of normal skin. A modest expression could be detected, however, in vessels and adnexae. On the contrary, PDGFRα and PDGFRβ were highly expressed in scleroderma skin. Expression of PDGFRα and PDGFRβ was detected mainly in spindle-like cells resembling fibroblasts, in vessels and in adnexae.
PDGFR staining in vessels and adnexae was not altered following RTX treatment, indicating that the effect of B-cell depletion therapy was specific to spindle-like cells.
The above data indicate that RTX mediates a significant attenuation of PDGFRα and PDGFRβ expression on spindle-like cells in the papillary dermis of patients with SSc.
Expression of phosphorylated (activated) PDGFR on spindle-like cells in scleroderma skin decreases following rituximab treatment
We next studied the expression of phosphorylated PDGFRα and PDGFRβ, which represent the activated forms of the receptor. Staining patterns for phospho-PDGFRα and phospho-PDGFRβ were the same as for PDGFRα and PDGFRβ. Expression of phosphorylated PDGFRα and PDGFRβ could not be detected in spindle-like cells in the dermis of normal skin; on the contrary, these receptors were highly expressed on spindle-like cells in scleroderma skin.
We next calculated the phospho-PDGFRα/PDGFRα ratio and the phospho-PDGFRβ/PDGFRβ ratio to assess the phosphorylation (activation) status of the receptor. We found that PDGFR on spindle-like cells is highly phosphorylated in scleroderma skin, in sharp contrast to normal skin where PDGFR and phospho-PDGFR are virtually undetectable (mean ± SEM: 0.89 ± 0.02 and 0.93 ± 0.02 for phospho-PDGFRα/PDGFRα and phospho-PDGFRβ/PDGFRβ, respectively). The ratios of phospho-PDGFRα/PDGFRα and phospho-PDGFRβ/PDGFRβ modestly declined following treatment with RTX; statistical significance was reached only for phospho-PDGFRβ/PDGFRβ (mean ± SEM at baseline vs. 6 months, respectively: phospho-PDGFRα/PDGFRα ratio, 0.92 ± 0.017 vs. 0.87 ± 0.02, P = 0.09; and phospho-PDGFRβ/PDGFRβ ratio, 0.93 ± 0.009 vs. 0.89 ± 0.019, P = 0.04).
The above data taken together indicate that RTX treatment not only mediates a significant attenuation of PDGFRα and PDGFRβ expression on spindle-like cells, but also associates with a decrease in PDGFRβ phosphorylation (activation) status.
Serum levels and tissue expression of PDGF is not altered by rituximab treatment
We next assessed whether the attenuation of PDGFR expression and activation reported above is mediated by changes in serum levels or tissue expression of PDGF. Serum levels of PDGF-AA and PDGF-BB did not change following RTX treatment (mean ± SEM optical density at baseline vs. 6 months, respectively: PDGF-AA, 0.68 ± 0.06 vs. 0.81 ± 0.09; and PDGF-BB, 0.32 ± 0.03 vs. 0.38 ± 0.09; P = not significant in both cases). Similarly, we found no changes in the expression of PDGF in the papillary dermis following RTX treatment (mean ± SEM at baseline vs. 6 months, respectively: PDGF-AA, 44.61 ± 3.63 vs. 47.06 ± 3.27; and PDGF-BB, 43.84 ± 5.44 vs. 44.59 ± 2.61; P = not significant in both cases).
These data suggest that the attenuation of PDGFR expression/activation in scleroderma skin, following RTX treatment, is not mediated by changes of its ligand in either peripheral blood or skin.
We report herein immunohistochemical evidence that RTX treatment in patients with SSc associates with a significant downregulation of PDGFRα and PDGFRβ expression on spindle-like cells in the skin and with attenuation of the PDGFRβ phosphorylation (activation) status. The biologic effect of RTX on PDGFR is noteworthy since PDGF and transforming growth factor beta are considered master regulators of the fibrotic process. An animal model with mutations in PDGFRα leading to excessive kinase activity was created recently. Interestingly, this animal model is characterized by a multiorgan fibrotic disease that has striking similarities with SSc . Moreover, irradiation-induced lung fibrosis in mice associates with a significant increase in PDGFR activation; blocking PDGFR signaling by specific tyrosine kinase inhibitors attenuates fibrosis and increases survival in these mice . Blockade of PDGFR signaling is also effective in other models, such as the bleomycin-induced mouse model  and the vanadium pentoxide-induced mouse model  of lung fibrosis, providing evidence for the pivotal role of this pathway. The central role of PDGFR signaling in fibrosis is further supported by the reports of the antifibrotic properties of imatinib mesylate, a kinase inhibitor that partially acts through PDGFRβ inhibition, in animal models . In patients with SSc, PDGF is highly expressed in the skin , in bronchoalveolar lavage fluid  as well as in peripheral blood .
In this study we found that PDGFR is highly phosphorylated (activated) in scleroderma skin, in sharp contrast to normal skin where phosphorylated PDGFR was undetectable. This is the first study to report the expression of the phosphorylated form of PDGFR in SSc; other studies have assessed the expression of PDGFR using antibodies not specific for the phosphorylated form of the receptor [27–29]. The strong correlation between PDGFR expression and collagen accumulation found in our study underscores the significant role of PDGFR in fibrosis. RTX induces a significant decrease in PDGFR expression and collagen accumulation. This effect seemed to be specific for RTX since PDGFR expression was not decreased in the control biopsies.
This study does not answer the question of how RTX affects the expression of PDGFR. One may hypothesize that RTX may act through elimination of agonistic anti-PDGFR autoantibodies. A direct answer to this question could be given by measurement of these autoantibodies in serum, prior to and following RTX administration, but measurement of these autoantibodies can only be made using complex and technically challenging bioassays. Nevertheless, if RTX mediates its beneficial effect on fibrosis through elimination of stimulatory autoantibodies, one would expect a more robust downregulation of PDGFRα and PDGFRβ phosphorylation (activation) status; on the contrary, we found a significant decrease in PDGFRα and PDGFRβ expression and only a modest attenuation of PDGFRβ phosphorylation. We therefore propose that other mechanisms may apply; RTX not only affects B cells but has a broader effect on the immune system.
Data regarding the clinical efficacy of RTX in SSc are encouraging. The Rituximab Group of the EULAR Scleroderma Trials and Research Group reported recently that B-cell depletion therapy favorably affects skin fibrosis (data derived from 72 SSc patients treated with RTX from 27 EULAR Scleroderma Trials and Research Group centers) . The data reported herein suggest that RTX may favorably affect skin fibrosis through attenuation of PDGFR expression and activation, and add further evidence in support of a disease-modifying role for RTX in SSc. A large-scale, randomized controlled study assessing the efficacy of RTX in SSc is therefore needed.
bovine serum albumin
enzyme-linked immunosorbent assay
platelet-derived growth factor
platelet-derived growth factor receptor
standard error of the mean
This work was supported by the Hellenic Society for Rheumatology, a nonprofitable organization.
- Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP: Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010, 49: 271-280. 10.1093/rheumatology/kep093.View ArticleGoogle Scholar
- Bosello S, De Santis M, Lama G, Spano C, Angelucci C, Tolusso B, Sica G, Ferraccioli G: B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010, 12: R54-10.1186/ar2965.PubMed CentralView ArticlePubMedGoogle Scholar
- Lafyatis R, Kissin E, York M, Farina G, Viger K, Fritzler MJ, Merkel PA, Simms RW: B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009, 60: 578-583. 10.1002/art.24249.PubMed CentralView ArticlePubMedGoogle Scholar
- Smith V, Van Praet JT, Vandooren B, Van der Cruyssen B, Naeyaert JM, Decuman S, Elewaut D, De Keyser F: Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010, 69: 193-197. 10.1136/ard.2008.095463.View ArticlePubMedGoogle Scholar
- Hasegawa M, Hamaguchi Y, Yanaba K, Bouaziz JD, Uchida J, Fujimoto M, Matsushita T, Matsushita Y, Horikawa M, Komura K, Takehara K, Sato S, Tedder TF: B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol. 2006, 169: 954-966. 10.2353/ajpath.2006.060205.PubMed CentralView ArticlePubMedGoogle Scholar
- Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, Sato S: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest. 2002, 109: 1453-1462.PubMed CentralView ArticlePubMedGoogle Scholar
- Asano N, Fujimoto M, Yazawa N, Shirasawa S, Hasegawa M, Okochi H, Tamaki K, Tedder TF, Sato S: B lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse. Am J Pathol. 2004, 165: 641-650. 10.1016/S0002-9440(10)63328-7.PubMed CentralView ArticlePubMedGoogle Scholar
- Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Tedder TF, Sato S: CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol. 2008, 172: 1650-1663. 10.2353/ajpath.2008.071049.PubMed CentralView ArticlePubMedGoogle Scholar
- Komura K, Yanaba K, Horikawa M, Ogawa F, Fujimoto M, Tedder TF, Sato S: CD19 regulates the development of bleomycin-induced pulmonary fibrosis in a mouse model. Arthritis Rheum. 2008, 58: 3574-3584. 10.1002/art.23995.View ArticlePubMedGoogle Scholar
- Bonner JC: Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004, 15: 255-273. 10.1016/j.cytogfr.2004.03.006.View ArticlePubMedGoogle Scholar
- Yi ES, Lee H, Yin S, Piguet P, Sarosi I, Kaufmann S, Tarpley J, Wang NS, Ulich TR: Platelet-derived growth factor causes pulmonary cell proliferation and collagen deposition in vivo. Am J Pathol. 1996, 149: 539-548.PubMed CentralPubMedGoogle Scholar
- Hoyle GW, Li J, Finkelstein JB, Eisenberg T, Liu JY, Lasky JA, Athas G, Morris GF, Brody AR: Emphysematous lesions, inflammation, and fibrosis in the lungs of transgenic mice overexpressing platelet-derived growth factor. Am J Pathol. 1999, 154: 1763-1775. 10.1016/S0002-9440(10)65432-6.PubMed CentralView ArticlePubMedGoogle Scholar
- Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006, 354: 2667-2676. 10.1056/NEJMoa052955.View ArticlePubMedGoogle Scholar
- Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980, 23: 581-590. 10.1002/art.1780230510.View ArticleGoogle Scholar
- Daoussis D, Liossis SN, Tsamandas A, Kalogeropoulou C, Paliogianni F, Sirinian C, Yiannopoulos G, Andonopoulos AP: Effect of long term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2011Google Scholar
- Tsamandas AC, Thomopoulos K, Zolota V, Kourelis T, Karatzas T, Ravazoula P, Tepetes K, Petsas T, Karavias D, Karatza C, Bonikos DS, Gogos C: Potential role of bcl-2 and bax mRNA and protein expression in chronic hepatitis type B and C: a clinicopathologic study. Mod Pathol. 2003, 16: 1273-1288. 10.1097/01.MP.0000097367.56816.5E.View ArticlePubMedGoogle Scholar
- Vis AN, Kranse R, Nigg AL, van der Kwast TH: Quantitative analysis of the decay of immunoreactivity in stored prostate needle biopsy sections. Am J Clin Pathol. 2000, 113: 369-373. 10.1309/CQWY-E3F6-9KDN-YV36.View ArticlePubMedGoogle Scholar
- Hatanaka Y, Hashizume K, Kamihara Y, Itoh H, Tsuda H, Osamura RY, Tani Y: Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTest™ in breast carcinoma by image analysis. Pathol Int. 2001, 51: 33-36. 10.1046/j.1440-1827.2001.01162.x.View ArticlePubMedGoogle Scholar
- Olson LE, Soriano P: Increased PDGFRα activation disrupts connective tissue development and drives systemic fibrosis. Dev Cell. 2009, 16: 303-313. 10.1016/j.devcel.2008.12.003.PubMed CentralView ArticlePubMedGoogle Scholar
- Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Grone HJ, Lipson KE, Huber PE: Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med. 2005, 201: 925-935. 10.1084/jem.20041393.PubMed CentralView ArticlePubMedGoogle Scholar
- Chaudhary NI, Roth GJ, Hilberg F, Muller-Quernheim J, Prasse A, Zissel G, Schnapp A, Park JE: Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J. 2007, 29: 976-985. 10.1183/09031936.00152106.View ArticlePubMedGoogle Scholar
- Rice AB, Moomaw CR, Morgan DL, Bonner JC: Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol. 1999, 155: 213-221. 10.1016/S0002-9440(10)65115-2.PubMed CentralView ArticlePubMedGoogle Scholar
- Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, Distler O, Distler JH: Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2009, 60: 219-224. 10.1002/art.24186.View ArticlePubMedGoogle Scholar
- Gay S, Jones RE, Huang GQ, Gay RE: Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol. 1989, 92: 301-303. 10.1111/1523-1747.ep12276895.View ArticlePubMedGoogle Scholar
- Ludwicka A, Ohba T, Trojanowska M, Yamakage A, Strange C, Smith EA, Leroy EC, Sutherland S, Silver RM: Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol. 1995, 22: 1876-1883.PubMedGoogle Scholar
- Pandolfi A, Florita M, Altomare G, Pigatto P, Donati MB, Poggi A: Increased plasma levels of platelet-derived growth factor activity in patients with progressive systemic sclerosis. Proc Soc Exp Biol Med. 1989, 191: 1-4.View ArticlePubMedGoogle Scholar
- Klareskog L, Gustafsson R, Scheynius A, Hallgren R: Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum. 1990, 33: 1534-1541. 10.1002/art.1780331011.View ArticlePubMedGoogle Scholar
- Zheng XY, Zhang JZ, Tu P, Ma SQ: Expression of platelet-derived growth factor B-chain and platelet-derived growth factor beta-receptor in fibroblasts of scleroderma. J Dermatol Sci. 1998, 18: 90-97. 10.1016/S0923-1811(98)00027-9.View ArticlePubMedGoogle Scholar
- Soria A, Cario-Andre M, Lepreux S, Rezvani HR, Pasquet JM, Pain C, Schaeverbeke T, Mahon FX, Taieb A: The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Dermatology. 2008, 216: 109-117. 10.1159/000111507.View ArticlePubMedGoogle Scholar
- Jordan S, Distler J, Maourer B, Allanore Y, van Laar J, Distler O: Safety and efficacy of Rituximab in SSC: an analysis from the European Trial and Research Group. Proceedings of the 2nd Systemic Sclerosis World Congress; February 2-4 2012; Madrid, Spain. 2012, Rheumatology, UK, 51 (Supplement 2): ii25-
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.